Joshua Allen
Directeur Technique/Scientifique/R&D chez CHIMERIX, INC.
Profil
Joshua E.
Allen is currently the Chief Technology Officer at Chimerix, Inc. Prior to his current position, he served as the Chief Scientific Officer at Oncoceutics, Inc. from 2003 to 2021.
Dr. Allen holds a doctorate degree from the University of Pennsylvania.
Postes actifs de Joshua Allen
| Sociétés | Poste | Début |
|---|---|---|
| CHIMERIX, INC. | Directeur Technique/Scientifique/R&D | 01/01/2021 |
Anciens postes connus de Joshua Allen
| Sociétés | Poste | Fin |
|---|---|---|
Oncoceutics, Inc.
 Oncoceutics, Inc. Pharmaceuticals: MajorHealth Technology Oncoceutics, Inc. operates as a clinical-stage biopharmaceutical company. It is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The firm develops technology and therapies including ONC201, for natural potent tumor suppressor pathways in human cancer. Oncoceutics was founded by Wafik El-Deiry, Wolfgang Oster and Lee T. Schalop in 2009 and is headquartered in Philadelphia, PA. | Directeur Technique/Scientifique/R&D | 01/01/2021 |
Formation de Joshua Allen
| University of Pennsylvania | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CHIMERIX, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Oncoceutics, Inc.
Oncoceutics, Inc. Pharmaceuticals: MajorHealth Technology Oncoceutics, Inc. operates as a clinical-stage biopharmaceutical company. It is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The firm develops technology and therapies including ONC201, for natural potent tumor suppressor pathways in human cancer. Oncoceutics was founded by Wafik El-Deiry, Wolfgang Oster and Lee T. Schalop in 2009 and is headquartered in Philadelphia, PA. | Health Technology |
